Manzo Pharmaceuticals Announces Plans for Human Clinical Studies of the Company’s Patented Lactose Intolerance Probiotic, Lacto-Freedom™
Manzo Pharmaceuticals, Inc. (MNZO), today announced Manzo Pharmaceuticals has identified Medicus Research to perform the human clinical study of Lacto-Freedom probiotic, a necessary step in order to take the ground breaking product to market.
The goal of this human study is to use science to substantiate that the Lacto-Freedom™ Probiotic demonstrates efficacy in decreasing symptoms of Lactose Intolerance when consuming a glass of milk. Dr. Jay Udani, CEO of Medicus Reseach, concurred that the FDA recognizes genetically modified probiotics, like Lacto-Freedom probiotic, as nutritional supplements and there are no additional regulations that pertain to genetically modified probiotics. Dr. Jay Udeni has expertise in FDA regulations, probiotics development and deployment, clinical studies, as well as Federal Trade Commission regulation compliance. Medicus Research designs its clinical trials to guarantee that its studies are structurally and functionally compliant, and follow the strict guidelines that are in place. Medicus has established Good Clinical Practice and FDA compliant procedures, internal quality assurance processes, and proprietary management technology systems, which ensure the highest quality for all aspects of the study. Consumers can find out more about Medicus at :https://www.medicusresearch.com/
Prior to this clinical trial Manzo Pharmaceuticals and Celprogen will run a small pilot study with a limited number of human subjects to make sure the dose is adequate and that no modifications in the study need to be made before commencing the formal in depth human clinical study. Once a successful human study is completed, Lacto-Freedom probiotic can go to market, and the company feels confident that it will change the lives of those suffering from lactose intolerance. Manzo Pharmaceuticals anticipates a successful human study and is already in talks with several manufacturers of probiotics to be ready to go straight to market.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose Intolerance, and a natural remedy for colic in babies. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-plans-for-human-clinical-studies-of-the-companys-patented-lactose-intolerance-probiotic-lacto-freedom-300048514.html
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
